1996> 1997> 1998 1999> 2000> 2001>

 
The National AIDS Treatment Advocacy Project - NATAP - provides the latest in HIV and AIDS drug research and treatment information as well as comprehensive reports and developments from the Fifth Retroviruses and Opportunistic Infections conference, as well as from the ICAR, ICAAC, IDSA, European and International HIV and AIDS conferences, and from other sources. 

     1998

HIGHLIGHTS FROM ICDCD:

DAILY HIGHLIGHTS FROM THE 4th INTERNATIONAL CONGRESS ON
DRUG THERAPY IN HIV INFECTION, GLASGOW, SCOTLAND:

A First Report in a Series on Resistance Testing; including a Geneva Report on Transmission of Protease Resistant Virus

 

DAILY HIGHLIGHTS FROM ICAAC:

  • Brief Overview of ICAAC Highlights
  • A Different Perspective on Lipodystrophy
  • Update on Lipid Abnormalities and Cardiovascular Complications in HIV Infection
  • Day One-Thursday: Sustiva Pricing; Remune; Agouron New NNRTI & PI
  • Day Two-Friday: Pharmacokinetcs (PK), New Drugs
  • Day Three-Saturday: Clinical Studies...including:
  • New Bristol-Myers Protease Inhibitor (pre-clinical),
    Efavirenz+AZT/3TC- 36 weeks follow-up,
    Nevirapine+ d4T/ddI,
    Nelfinavir+Efavirenz,
    Indinavir+Efavirenz 84 weeks,
    Fortovase BID,
    Adefovir
  • New NNRTI and PI from Agouron: preliminary data
  • D4T+DDI+Nevirapine: 24 Weeks
  • Switch/Intensification Treatment with Combivir (AZT/3TC) and Abacavir in NRTI-Experienced Individuals
  • Prospective Follow-up of 130 HIV-Infected Patients Treated Early with Combination of 2 NRTIS
  • Fortovase BID Regimen in Combination With 2 NRTIs or Nelfinavir plus 1 NRTI
  • Late Breaker--Amprenavir (141W94) + AZT/3TC: 16 week data in treatment-naive
  • Increased Rate of HIV-1 Elimination with a Four-Drug Antiretroviral Regimen in Treatment-Naive Patients
  • Efavirenz + AZT/3TC: 36 week Update
  • >

    Fifth Retroviruses & Opportunistic Infections Conference, Chicago, February 1-5, 1998

    • Protease Inhibitor and Viral Load Strategy Update a ten-part report including reducing viral load to <50 copies/ml; Does rapid reduction of viral load promote durability?; In vitro cross-resistance: PIS and NRTIs; Paterns of Protease Inhibitor cross-resistance in 500 clinical isolates; Triple NRTI therapy during primary infection; SGC; Invirase vs Fortovase; and Fortovase vs Crixivan; Nelfinavir studies; 141W94; the potential for limiting or preventing PI cross-resistance by switching PIs immediately after viral load rebound (04/28/98)

    • NRTI Report including comparisons of D4T/3TC vs AZT/3TC both with Indinavir; comparisions of D4T/DDI vs AZT/3TC both with Indinavir; 1592U89 Resistance and phenotypic testing; 1592 and Indinavir, Nelfinavir, SGC or 141W94, 2 drug combination; and New NRTI's in early development (04/28/98)
    • NNRTI update: Reports on Efavirenz (EFV); NNRTI Resistance; and Nevirapine (NVP) (04/12/98)
    • Efavirenz (EFV) Reports includes PK effect of EFV on 141W94; 60 week data on EFV + Indinavir; 24 week data on EFV + AZT/3TC; and EFV CSF Levels in Monkeys (04/12/98)
    pdf
  • Double Protease Combinations (03/09/98) including: Ritonavir + Saquinavir; Nelfinavir + Saquinavir;  Indinavir + Nelfinavir; Ritonavir + Nelfinavir; 141+IDV, NFV, or SQV; and Commentary on Treating Protease Resistant Virus.
  • pdf
    pdf

    Reports + Developments from ICAAC, IDSA, and Hamburg conferences

     
    • Hydroxyurea (HU)
    Safety and Antiviral Activity of Hydroxyurea (HU) with ddI (1/21/98)

    pdf

    Hydroxyurea as a Novel Approach to HIV Therapy, #2 (1/21/98)

    pdf

    Reduction of the IC50 of ddI by Hydroxyurea (HU) against HIV (1/21/98)

    pdf

    Hydroxyurea + d4T/ddI vs d4T/ddI (1/21/98)

    pdf

    • Protease Inhibitors
    Protease Inhibitors & Pediatrics (1/21/98) pdf
    Protease Inhibitors: success and resistance, salvage therapy, data updates, new Upjohn PI (1/21/98) pdf
    141W94 (VX-478) (1/21/98) pdf
    In Vitro Effect of HIV Protease Inhibitors on Methadone Metabolism (1/21/98) pdf
    Twice Daily Dosing Studies: Indinavir, Nelfinavir, Saquinavir (1/21/98) pdf
    Crixivan + ddI and d4T (1/21/98) pdf
    Impact of HIV Protease Inhibitors on HCV Viremia (1/21/98) pdf
    Saquinavir SGC (Fortovase): EOF, New Formulation (1/21/98) pdf
    • Double Protease combinations
    Double Protease Combinations (1/21/98) pdf
    • Nucleosides
    1592U89 (abacavir): efficacy and resistance data (1/21/98) pdf
    Nucleosides: (1) d4T + ddI following pretreatment with AZT + ddC; (2) ACTG306: d4T + 3TC vs AZT + 3TC; (3) d4T + 3TC or d4T + ddI vs AZT + 3TC (1/21/98) pdf
    • CSF and Anti-retroviral HIV Treatment
    The CSF and Indinavir, Ritonavir + Saquinavir, DMP-266, 1592U89, AZT vs d4T (1/21/98) pdf
    • Non-Nucleoside Treatment Information
    DMP-266: (efavirenz, Sustiva-brand name) (1/21/98 pdf
    Nevirapine + Indinavir (1/21/98) pdf
    Delavirdine Interactions with Nelfinavir and Ritonavir: Delavirdine + AZT/3TC vs. AZT/3TC (1/21/98) pdf
    • Other

    Laboratories That Offer the Ultra-sensitive PCR Test to Individuals (1/21/98)

    pdf
    MKC-442 and PMEA (1/21/98) pdf
    NATAP Resistance Supplement - Part I (1/21/98) pdf

    Salvage Therapy with 6 Drugs (1/21/98)

    pdf
    T-20 (1/21/98) pdf

    The Real Deal on the ICAAC Report by Steven Deeks of 53% Protease Inhibitors Failure Rate (1/21/98)

    pdf
    Viral Load Issues and Strategies (1/21/98) pdf
    Effect of Influenza Vaccination on HIV RNA (1/21/98) pdf

    Impact of HAART on Opportunistic Infections (ICAAC) (1/21/98)

    pdf

    FIFTH RETROVIRUSES &
    OPPORTUNISTIC INFECTIONS CONFERENCE
    Chicago, February 1-5, 1998

    • Double Protease Combinations (03/09/98) including: Ritonavir + Saquinavir; Nelfinavir + Saquinavir;  Indinavir + Nelfinavir; Ritonavir + Nelfinavir; 141+IDV, NFV, or SQV; and Commentary on Treating Protease Resistant Virus.
    pdf
    pdf
    1996> 1997> 1998 1999> 2000> 2001>